NCT02683889CompletedPhase 3
Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation
The Use of Acthar (ACTH) in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Have Developed Chronic Kidney Disease Stage V (CKD) or End Stage Renal Disease (ESRD) and Are Undergoing a Renal Transplant
Source: ClinicalTrials.gov · Last updated 1 Jul 2026
Brief summary (registry, in English)
This study will evaluate the use of Acthar in patients to undergo renal transplantation and will measure the rate of FSGS recurrence.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 15 (actual)
- First submitted
- 5 Feb 2016
- Start date
- 1 Feb 2019
- Primary completion date
- 6 Jun 2024
- Lead sponsor
- University of Colorado, Denver
- Diseases
- Chronic kidney disease
- NCT number
- NCT02683889
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 15
- From 1 Feb 2019 to the primary completion date, 6 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Not having FSGS
Who the study is looking for
- FSGS
- To receive either a live donor or deceased donor kidney transplant
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medstar Georgetown Transplant Institute Coordinator of this site? Confirm its status | Washington D.C. | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.